Clinical trial
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With…
NCT00485719 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00485719 |
|---|---|
| Title | Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors |
| Official title | A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | XL765 (SAR245409) |
| Enrollment | 83 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Jun 13, 2007 |
| Last update posted | May 30, 2013 |
| Countries | Spain, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: